Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials

Background: Adjuvant radiotherapy after breast-conserving surgery is indicated in the vast majority of breast cancer patients. Conventionally fractionated radiotherapy with 50 Gy in 25 fractions was considered standard of care for several decades. The recently publishes long-term results of randomiz...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast care (Basel, Switzerland) Switzerland), 2015-01, Vol.10 (4), p.240-245
Hauptverfasser: Budach, Wilfried, Bölke, Edwin, Matuschek, Christiane
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 245
container_issue 4
container_start_page 240
container_title Breast care (Basel, Switzerland)
container_volume 10
creator Budach, Wilfried
Bölke, Edwin
Matuschek, Christiane
description Background: Adjuvant radiotherapy after breast-conserving surgery is indicated in the vast majority of breast cancer patients. Conventionally fractionated radiotherapy with 50 Gy in 25 fractions was considered standard of care for several decades. The recently publishes long-term results of randomized trials that have tested different moderately hypofractionated radiotherapy schedules that may change clinical practice. Patients and Methods: A Pubmed search was carried out to identify the relevant publications on hypofractionated radiotherapy in breast cancer. In total, 4 randomized controlled trials representing the results of 7,095 patients with 10 years of follow-up were identified. A meta-analysis on the primary end point ipsilateral breast cancer recurrence and a review of the toxicity data were performed. Results: Moderately hypofractionated radiotherapy using schedules such as 40 Gy in 15 fractions administered within 3 weeks are as efficient and safe as conventionally fractionated radiotherapy for most breast cancer patients who need adjuvant radiotherapy after breast-conserving surgery. In patients aged < 40 years, after neoadjuvant chemotherapy, and if regional lymph node radiotherapy is indicated, further data are needed. Conclusion: Moderately hypofractionated radiotherapy can be recommended as standard treatment after breast-conserving surgery in the majority of breast cancer patients.
doi_str_mv 10.1159/000439007
format Article
fullrecord <record><control><sourceid>pubmed_karge</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4608603</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>26600759</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-fcfec20db7816afc514d76be215dbf10d31a84081ad1c7727b87849949b2eba23</originalsourceid><addsrcrecordid>eNptkU1r3DAQhkVoyfch9xIEPeXgRPKHZF8KG5M0hZTAsjmbsT4SpV7JSMoW5wfkd0dlG9NAT_My88w7zAxCJ5ScU1o1F4SQsmgI4TtonzJGs6Im1ad3zRu6hw5CeEoUKzjbRXs5Y4mumn30ejONTnsQ0TgLUUm8BGlcfFQexglDwAv59LwBG_HKK4hrlZSx-Ar8MOHLlAoRt2CF8ud4gZdqY9RvDFbinypCtrAwTMEE7HQyttKtzUua0TobvRuGJFfewBCO0Gedgjr-Gw_R_fXVqr3Jbu--_2gXt5koKx4zLbQSOZE9rykDLSpaSs56ldNK9poSWVCoS1JTkFRwnvO-5nXZNGXT56qHvDhE37a-43O_VlKkbTwM3ejNGvzUOTDdx4o1j92D23QlIzUjRTI42xoI70LwSs-9lHR_ntHNz0js6b_DZvL9-gn4sgV-gX9Qfgbm_q__LV8u2y3RjVIXbygrnK0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials</title><source>Karger Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Budach, Wilfried ; Bölke, Edwin ; Matuschek, Christiane</creator><creatorcontrib>Budach, Wilfried ; Bölke, Edwin ; Matuschek, Christiane</creatorcontrib><description>Background: Adjuvant radiotherapy after breast-conserving surgery is indicated in the vast majority of breast cancer patients. Conventionally fractionated radiotherapy with 50 Gy in 25 fractions was considered standard of care for several decades. The recently publishes long-term results of randomized trials that have tested different moderately hypofractionated radiotherapy schedules that may change clinical practice. Patients and Methods: A Pubmed search was carried out to identify the relevant publications on hypofractionated radiotherapy in breast cancer. In total, 4 randomized controlled trials representing the results of 7,095 patients with 10 years of follow-up were identified. A meta-analysis on the primary end point ipsilateral breast cancer recurrence and a review of the toxicity data were performed. Results: Moderately hypofractionated radiotherapy using schedules such as 40 Gy in 15 fractions administered within 3 weeks are as efficient and safe as conventionally fractionated radiotherapy for most breast cancer patients who need adjuvant radiotherapy after breast-conserving surgery. In patients aged &lt; 40 years, after neoadjuvant chemotherapy, and if regional lymph node radiotherapy is indicated, further data are needed. Conclusion: Moderately hypofractionated radiotherapy can be recommended as standard treatment after breast-conserving surgery in the majority of breast cancer patients.</description><identifier>ISSN: 1661-3791</identifier><identifier>EISSN: 1661-3805</identifier><identifier>DOI: 10.1159/000439007</identifier><identifier>PMID: 26600759</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Review ; Review Article</subject><ispartof>Breast care (Basel, Switzerland), 2015-01, Vol.10 (4), p.240-245</ispartof><rights>2015 S. Karger GmbH, Freiburg</rights><rights>Copyright © 2015 by S. Karger AG, Basel 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-fcfec20db7816afc514d76be215dbf10d31a84081ad1c7727b87849949b2eba23</citedby><cites>FETCH-LOGICAL-c457t-fcfec20db7816afc514d76be215dbf10d31a84081ad1c7727b87849949b2eba23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608603/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608603/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,2423,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26600759$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Budach, Wilfried</creatorcontrib><creatorcontrib>Bölke, Edwin</creatorcontrib><creatorcontrib>Matuschek, Christiane</creatorcontrib><title>Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials</title><title>Breast care (Basel, Switzerland)</title><addtitle>Breast Care</addtitle><description>Background: Adjuvant radiotherapy after breast-conserving surgery is indicated in the vast majority of breast cancer patients. Conventionally fractionated radiotherapy with 50 Gy in 25 fractions was considered standard of care for several decades. The recently publishes long-term results of randomized trials that have tested different moderately hypofractionated radiotherapy schedules that may change clinical practice. Patients and Methods: A Pubmed search was carried out to identify the relevant publications on hypofractionated radiotherapy in breast cancer. In total, 4 randomized controlled trials representing the results of 7,095 patients with 10 years of follow-up were identified. A meta-analysis on the primary end point ipsilateral breast cancer recurrence and a review of the toxicity data were performed. Results: Moderately hypofractionated radiotherapy using schedules such as 40 Gy in 15 fractions administered within 3 weeks are as efficient and safe as conventionally fractionated radiotherapy for most breast cancer patients who need adjuvant radiotherapy after breast-conserving surgery. In patients aged &lt; 40 years, after neoadjuvant chemotherapy, and if regional lymph node radiotherapy is indicated, further data are needed. Conclusion: Moderately hypofractionated radiotherapy can be recommended as standard treatment after breast-conserving surgery in the majority of breast cancer patients.</description><subject>Review</subject><subject>Review Article</subject><issn>1661-3791</issn><issn>1661-3805</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNptkU1r3DAQhkVoyfch9xIEPeXgRPKHZF8KG5M0hZTAsjmbsT4SpV7JSMoW5wfkd0dlG9NAT_My88w7zAxCJ5ScU1o1F4SQsmgI4TtonzJGs6Im1ad3zRu6hw5CeEoUKzjbRXs5Y4mumn30ejONTnsQ0TgLUUm8BGlcfFQexglDwAv59LwBG_HKK4hrlZSx-Ar8MOHLlAoRt2CF8ud4gZdqY9RvDFbinypCtrAwTMEE7HQyttKtzUua0TobvRuGJFfewBCO0Gedgjr-Gw_R_fXVqr3Jbu--_2gXt5koKx4zLbQSOZE9rykDLSpaSs56ldNK9poSWVCoS1JTkFRwnvO-5nXZNGXT56qHvDhE37a-43O_VlKkbTwM3ejNGvzUOTDdx4o1j92D23QlIzUjRTI42xoI70LwSs-9lHR_ntHNz0js6b_DZvL9-gn4sgV-gX9Qfgbm_q__LV8u2y3RjVIXbygrnK0</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Budach, Wilfried</creator><creator>Bölke, Edwin</creator><creator>Matuschek, Christiane</creator><general>S. Karger AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials</title><author>Budach, Wilfried ; Bölke, Edwin ; Matuschek, Christiane</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-fcfec20db7816afc514d76be215dbf10d31a84081ad1c7727b87849949b2eba23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Review</topic><topic>Review Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Budach, Wilfried</creatorcontrib><creatorcontrib>Bölke, Edwin</creatorcontrib><creatorcontrib>Matuschek, Christiane</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast care (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Budach, Wilfried</au><au>Bölke, Edwin</au><au>Matuschek, Christiane</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials</atitle><jtitle>Breast care (Basel, Switzerland)</jtitle><addtitle>Breast Care</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>10</volume><issue>4</issue><spage>240</spage><epage>245</epage><pages>240-245</pages><issn>1661-3791</issn><eissn>1661-3805</eissn><abstract>Background: Adjuvant radiotherapy after breast-conserving surgery is indicated in the vast majority of breast cancer patients. Conventionally fractionated radiotherapy with 50 Gy in 25 fractions was considered standard of care for several decades. The recently publishes long-term results of randomized trials that have tested different moderately hypofractionated radiotherapy schedules that may change clinical practice. Patients and Methods: A Pubmed search was carried out to identify the relevant publications on hypofractionated radiotherapy in breast cancer. In total, 4 randomized controlled trials representing the results of 7,095 patients with 10 years of follow-up were identified. A meta-analysis on the primary end point ipsilateral breast cancer recurrence and a review of the toxicity data were performed. Results: Moderately hypofractionated radiotherapy using schedules such as 40 Gy in 15 fractions administered within 3 weeks are as efficient and safe as conventionally fractionated radiotherapy for most breast cancer patients who need adjuvant radiotherapy after breast-conserving surgery. In patients aged &lt; 40 years, after neoadjuvant chemotherapy, and if regional lymph node radiotherapy is indicated, further data are needed. Conclusion: Moderately hypofractionated radiotherapy can be recommended as standard treatment after breast-conserving surgery in the majority of breast cancer patients.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>26600759</pmid><doi>10.1159/000439007</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1661-3791
ispartof Breast care (Basel, Switzerland), 2015-01, Vol.10 (4), p.240-245
issn 1661-3791
1661-3805
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4608603
source Karger Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Review
Review Article
title Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T22%3A32%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypofractionated%20Radiotherapy%20as%20Adjuvant%20Treatment%20in%20Early%20Breast%20Cancer.%20A%20Review%20and%20Meta-Analysis%20of%20Randomized%20Controlled%20Trials&rft.jtitle=Breast%20care%20(Basel,%20Switzerland)&rft.au=Budach,%20Wilfried&rft.date=2015-01-01&rft.volume=10&rft.issue=4&rft.spage=240&rft.epage=245&rft.pages=240-245&rft.issn=1661-3791&rft.eissn=1661-3805&rft_id=info:doi/10.1159/000439007&rft_dat=%3Cpubmed_karge%3E26600759%3C/pubmed_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/26600759&rfr_iscdi=true